News: GlaxoSmithKline

06.09.2010 | Medical News Today: Seasonal Influenza Vaccine Distribution Still Below Levels Needed To Meet Guidelines, Despite Growth Worldwide

A new IFPMA study(1), announced at the "Options for the Control of Influenza VII" conference in Hong Kong, shows that global vaccine coverage remains uneven and low overall, despite total distribution of seasonal influenza vaccines nearly doubling over the last six years. The (…)

[Read article]

[Source: Medical News Today]

06.09.2010 | Medical News Today: Concern About Rosiglitazone (Avandia) And How Drugs Are Regulated And Promoted, BMJ

There is serious concern about top-selling diabetes drug rosiglitazone (Avandia), its safety, as well as the whole system by which medications are regulated, evaluated and promoted worldwide, according to a BMJ (British Medical Journal) investigation. Dr. Fiona Godlee, BMJ (…)

[Read article]

[Source: Medical News Today]

06.09.2010 | Business Wire: Research and Markets: Men's Health Therapeutics Market to 2016 - in-Depth Analysis of the Unmet Needs, Drivers & Barriers Affecting the Men's Health Market | Business Wire

DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/e3fec8/mens_health_thera) has announced the addition of the "Men's Health Therapeutics Market to 2016 - Selective Serotonin Reuptake Inhibitors, Hormone Replacement Therapy and (…)

[Read article]

[Source: Business Wire]

06.09.2010 | Business Wire: Research and Markets: Cancer Drug Resistance Report: the Single Most Important Cause of Cancer Treatment Failure | Business Wire

DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/41867b/cancer_drug_resist) has announced the addition of the "Cancer Drug Resistance" report to their offering. Drug resistance is the single most important cause of cancer treatment (…)

[Read article]

[Source: Business Wire]

03.09.2010 | Business Wire: Exelixis Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) | Business Wire

SOUTH SAN FRANCISCO, Calif.-(BUSINESS WIRE)-Exelixis, Inc. (Nasdaq:EXEL) announced that today it granted restricted stock units representing an aggregate of 25,200 shares of Exelixis common stock to nine new employees. The restricted stock unit awards vest as to 1/4th of the (…)

[Read article]

[Source: Business Wire]

03.09.2010 | Business Wire: Research and Markets: Thailand Pharmaceuticals and Healthcare Report Q4 2010 | Business Wire

DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/60383e/thailand_pharmaceu) has announced the addition of the "Thailand Pharmaceuticals and Healthcare Report Q4 2010" report to their offering. Thailand Pharmaceuticals and Healthcare (…)

[Read article]

[Source: Business Wire]

03.09.2010 | Business Wire: XenoPort Announces New Employment Inducement Award | Business Wire

SANTA CLARA, Calif.-(BUSINESS WIRE)-XenoPort, Inc. reported today that an equity award was made to a new employee subject to the terms and conditions of the XenoPort 2010 Inducement Award Plan. The employee was granted restricted stock units representing an aggregate of 750 (…)

[Read article]

[Source: Business Wire]

02.09.2010 | Business Wire: Research and Markets: Examine Norway's Pharmaceutical Market with This Essential Analysis to 2014 As the Market Generated Total Revenues of $2,011.5 Million In 2009 | Business Wire

DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/ebf598/norway_pharmaceuti) has announced the addition of the "Norway Pharmaceutical Market Analysis, 2010-2014" report to their offering. Having displayed fluctuating growth rates in the (…)

[Read article]

[Source: Business Wire]

02.09.2010 | BioSpace: Seattle Genetics, Inc. (SGEN) Achieves Milestone under Antibody-Drug Conjugate Collaboration with Agensys, Inc., an Affiliate of Astellas Pharma Inc. (YPH.BE); Seattle Has Received $130 Million to date With Potential to Receive $2.7 Billion

BOTHELL, Wash.-(BUSINESS WIRE)-Seattle Genetics, Inc. (Nasdaq: SGEN - News) announced today that it has achieved a milestone under its antibody-drug conjugate (ADC) collaboration with Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc. The milestone was triggered (…)

[Read article]

[Source: BioSpace]

02.09.2010 | BioSpace: Addex Pharmaceuticals (ADXN.SW) Drug-Candidate Effective in Alzheimer's Disease Model

GENEVA, SWITZERLAND-(Marketwire - September 02, 2010) - Addex Pharmaceuticals / Addex drug-candidate effective in Alzheimer's disease model processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement. Allosteric modulation (…)

[Read article]

[Source: BioSpace]

01.09.2010 | Marketwire: Theravance to Present at Investor Conferences in September 2010

SOUTH SAN FRANCISCO, CA-(Marketwire - September 1, 2010) - Theravance, Inc. (NASDAQ: THRX) announced today that its Chief Executive Officer, Rick E Winningham, is scheduled to present at the following investor conferences in September 2010: Morgan Stanley Global Healthcare (…)

[Read article]

[Source: Marketwire]

01.09.2010 | Marketwire: Equity Research on GlaxoSmithKline and Abbott Laboratories - The Emerging Markets Opportunities

JOHANNESBURG, SOUTH AFRICA-(Marketwire - September 1, 2010) - www.stockcall.com/ offers investors comprehensive research on the major drug manufacturers industry and has completed analytical research on GlaxoSmithKline (NYSE: GSK) and Abbott Laboratories (NYSE: ABT). Register (…)

[Read article]

[Source: Marketwire]

01.09.2010 | Medical News Today: GSK And Valeant Announce New U.S. FDA PDUFA Goal Date For Ezogabine

GlaxoSmithKline (NYSE: GSK) and Valeant Pharmaceuticals International (NYSE: VRX) announced the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for ezogabine to 30 November 2010. The original goal date was 30 August (…)

[Read article]

[Source: Medical News Today]

01.09.2010 | Business Wire: Research and Markets: Argentina Pharmaceuticals and Healthcare Report Q4 2010 | Business Wire

DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/2745c9/argentina_pharmace) has announced the addition of the "Argentina Pharmaceuticals and Healthcare Report Q4 2010" report to their offering. Argentina Pharmaceuticals and Healthcare (…)

[Read article]

[Source: Business Wire]

31.08.2010 | ScienceDaily: Lower-Dose Heparin Use During Coronary Procedure Does Not Appear to Reduce Risk of Major Bleeding

ScienceDaily (Aug. 31, 2010) A landmark international study, coordinated by McMaster University, has found that lower doses of a blood thinner called unfractionated heparin (UFH) during angioplasty did not reduce bleeding or vascular complications compared to standard dose UFH (…)

[Read article]

[Source: ScienceDaily]

31.08.2010 | Business Wire: Research and Markets: Philippines Pharmaceuticals and Healthcare Report Q4 2010 | Business Wire

DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/66a1b1/philippines_pharma) has announced the addition of the "Philippines Pharmaceuticals and Healthcare Report Q4 2010" report to their offering. Philippines Pharmaceuticals and (…)

[Read article]

[Source: Business Wire]

31.08.2010 | Business Wire: Research and Markets: Australia Pharmaceuticals and Healthcare Report Q4 2010 | Business Wire

DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/c31cef/australia_pharmace) has announced the addition of the "Australia Pharmaceuticals and Healthcare Report Q4 2010" report to their offering. Australia Pharmaceuticals and Healthcare (…)

[Read article]

[Source: Business Wire]

31.08.2010 | Business Wire: Research and Markets: Nigeria Pharmaceuticals and Healthcare Report Q4 2010 | Business Wire

DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/23871e/nigeria_pharmaceut) has announced the addition of the "Nigeria Pharmaceuticals and Healthcare Report Q4 2010" report to their offering. Nigeria Pharmaceuticals and Healthcare Report (…)

[Read article]

[Source: Business Wire]

31.08.2010 | Business Wire: Research and Markets: Poland Pharmaceuticals and Healthcare Report Q4 2010 | Business Wire

DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/46792f/poland_pharmaceuti) has announced the addition of the "Poland Pharmaceuticals and Healthcare Report Q4 2010" report to their offering. Poland Pharmaceuticals and Healthcare Report (…)

[Read article]

[Source: Business Wire]

31.08.2010 | BioSpace: Vivalis Publishes Its Results For The First Half And Confirms 2010 Targets

NANTES, FRANCE-(Marketwire - August 31, 2010) - Highlighted Links companynewsgroup Home PageVIVALIS (NYSE Euronext: VLS), a biopharmaceutical company, today announced its consolidated accounts (IFRS) for the first half of 2010 ended June 30, as well as its strategic (…)

[Read article]

[Source: BioSpace]

31.08.2010 | BioSpace: Flagship Biosciences LLC Creates Scientific Advisory Board

Flagstaff, AZ (PRWEB) August 27, 2010 - Flagship Biosciences LLC, a provider of digital pathology services, has formed a Scientific Advisory Board composed of experienced leaders in the pharmaceutical industry. Flagship is a pathologist-owned company committed to improving the (…)

[Read article]

[Source: BioSpace]

31.08.2010 | BioSpace: GlaxoSmithKline (GSK), Valeant Pharmaceuticals International (VRX) Face US Delay for Epilepsy Drug, Receives New PDUFA Date

LONDON, RESEARCH TRIANGLE PARK, N.C., and ALISO VIEJO, Calif., Aug. 30 /PRNewswire-FirstCall/ - GlaxoSmithKline (NYSE:GSK - News) and Valeant Pharmaceuticals International (NYSE:VRX - News) announced today the U.S. Food and Drug Administration (FDA) has extended the (…)

[Read article]

[Source: BioSpace]

31.08.2010 | BioSpace: Conway Reaches Settlement With GlaxoSmithKline (GSK) for $3.75 Million

Bizjournals - Kentucky Attorney General Jack Conway s office has reached a $3.75 million settlement between the state and GlaxoSmithKline PLC over the alleged deceptive or false marketing of the drugmaker s anti-nausea medications, most notably Kytril and Zofran.

[Read article]

[Source: BioSpace]

30.08.2010 | ScienceDaily: 'Toolbox of MiniPromoters' for Gene Research and Therapy Created

ScienceDaily (Aug. 30, 2010) University of British Columbia researchers have led the development of a new toolbox of MiniPromoters for research and future therapies on brain, spinal cord and eye function. See Also: Health & Medicine Personalized Medicine Gene Therapy Genes Mind (…)

[Read article]

[Source: ScienceDaily]

30.08.2010 | Business Wire: Research and Markets: This Essential Analysis Examines the Historical and Forecast Performance for Eli Lilly In the Prescription Pharma Sector | Business Wire

DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/37adf0/eli_lilly_co_p) has announced the addition of the "Eli Lilly & Co.: PharmaVitae Profile" company profile to their offering. Introduction This analysis examines the historical and (…)

[Read article]

[Source: Business Wire]

30.08.2010 | Business Wire: Research and Markets: This Report Highlights Sweden's Pharmaceutical Sector in Terms of Market Share, Key Trends, Market Players and Competitive Scenario in the Market | Business Wire

DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/b87073/sweden_pharmaceuti) has announced the addition of the "Sweden Pharmaceutical Market Analysis, 2010-2014" report to their offering. Having displayed fluctuating growth rates in the (…)

[Read article]

[Source: Business Wire]

30.08.2010 | Business Wire: Research and Markets: This Analysis Examines the Historical and Forecast Performance for GlaxoSmithKline in the Prescription Pharmaceutical Sector | Business Wire

DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/ac67d7/glaxosmithkline_pl) has announced the addition of the "GlaxoSmithKline plc: PharmaVitae Profile" company profile to their offering. This analysis examines the historical and (…)

[Read article]

[Source: Business Wire]

30.08.2010 | Business Wire: Research and Markets: Stakeholder Opinions: Sexually Transmitted Diseases - An Underestimated Threat Lacking Interventions to Prevent Transmission | Business Wire

DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/f02991/stakeholder_opinio) has announced the addition of the "Stakeholder Opinions: Sexually Transmitted Diseases - An Underestimated Threat Lacking Interventions to Prevent Transmission" (…)

[Read article]

[Source: Business Wire]

30.08.2010 | Business Wire: Research and Markets: This Analysis Examines the Historical and Forecast Performance for Johnson & Johnson in the Ethical Pharmaceutical Sector | Business Wire

DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/aabcf1/johnson_johnson) has announced the addition of the "Johnson & Johnson: PharmaVitae Profile" company profile to their offering. Introduction This analysis examines the historical and (…)

[Read article]

[Source: Business Wire]

27.08.2010 | Medical News Today: Wall Street Journal Reports On Pharma's Growing Interest In Emerging Markets

"Abbott Laboratories will soon acquire the biggest share of India's pharmaceuticals market, about 7%, when the company closes as early as next month on a $3.7 billion takeover of the drugs business of Piramal Healthcare Ltd.," the Wall Street Journal reports in an article that (…)

[Read article]

[Source: Medical News Today]

27.08.2010 | Medical News Today: Is Flu Jab Pandemrix Linked To Narcolepsy? European Medicines Agency Investigates

The European Commission asked the European Medicines Agency (EMEA) to investigate whether GlaxoSmithKline's flu jab, Panemrix is linked to a higher risk of developing narcoplepsy. The EMEA says the investigation is now underway. Some cases of narcolepsy were reported in Finland (…)

[Read article]

[Source: Medical News Today]

27.08.2010 | Business Wire: Research and Markets: Type 2 Diabetes - Pipeline Assessment and Market Forecasts to 2017 | Business Wire

DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/db0b08/type_2_diabetes) has announced the addition of GlobalData 's new report "Type 2 Diabetes - Pipeline Assessment and Market Forecasts to 2017" to their offering. Type 2 Diabetes - (…)

[Read article]

[Source: Business Wire]

25.08.2010 | NCBI PubMed: Function and efficacy of an {alpha}4-integrin antagonist using bioluminescence imaging to detect leukocyte trafficking in murine experimental colitis.

Leukocyte trafficking is a therapeutic target in IBD. The integrins alpha4beta7 and alpha4beta1 regulate leukocyte migration into tissues and lymphoid organs. Current strategies rely on biologics, such as mAb, to inhibit leukocyte recruitment. Here we show the in vivo (…)

[Read article]

[Source: NCBI PubMed]

23.08.2010 | NCBI PubMed: Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study.

BACKGROUND: Eltrombopag is an oral thrombopoietin receptor agonist for the treatment of thrombocytopenia. We aimed to compare the response to once daily eltrombopag versus placebo in patients with chronic immune thrombocytopenia during a 6-month period. METHODS: We undertook a (…)

[Read article]

[Source: NCBI PubMed]

15.09.2010 | NCBI PubMed: Quantitation of a de-fluorinated analogue of Casopitant Mesylate by normal-phase liquid chromatography/mass spectrometry.

The introduction of Quality by Design (QbD) in Drug Development has resulted in a greater emphasis on chemical process understanding, in particular on the origin and fate of impurities. Therefore, the identification and quantitation of low level impurities in new Active (…)

[Read article]

[Source: NCBI PubMed]

26.08.2010 | NCBI PubMed: Rationalizing fragment based drug discovery for BACE1: insights from FB-QSAR, FB-QSSR, multi objective (MO-QSPR) and MIF studies.

The ability to identify fragments that interact with a biological target is a key step in FBDD. To date, the concept of fragment based drug design (FBDD) is increasingly driven by bio-physical methods. To expand the boundaries of QSAR paradigm, and to rationalize FBDD using In (…)

[Read article]

[Source: NCBI PubMed]

25.08.2010 | NCBI PubMed: New and emerging technologies for genetic toxicity testing.

The International Life Sciences Institute (ILSI) Health and Environmental Sciences Institute (HESI) Project Committee on the Relevance and Follow-up of Positive Results in In Vitro Genetic Toxicity (IVGT) Testing established an Emerging Technologies and New Strategies Workgroup (…)

[Read article]

[Source: NCBI PubMed]

26.08.2010 | NCBI PubMed: Recent Advances in the Discovery of Selective AMPA Receptor Positive Allosteric Modulators.

This article highlights recent advances in the discovery of new positive allosteric modulators of the AMPA receptor, excluding compounds of thiadiazine chemotype, most of which were developed by Servier and the University of Liège. The field of AMPA receptor modulators (…)

[Read article]

[Source: NCBI PubMed]

27.08.2010 | BioSpace: EU Drugs Regulator Reviews Safety of GlaxoSmithKline (GSK)'s Flu Jab, Probes Swine Flu Shot, Narcolepsy Link

LONDON (Reuters) - Europe's drug regulator is reviewing the safety of GlaxoSmithKline's Pandemrix flu vaccine, which has been given to more than 30 million people in Europe, to investigate possible links to a sleep disorder.

[Read article]

[Source: BioSpace]

26.08.2010 | Medical News Today: Increased Generic Erosion Of Key Agents Such As Lamictal And Depakote/Depakote ER Will Cause A $2.3 Billion Decline In The Drug Market

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the increased generic erosion of key drugs such as lamotrigine (GlaxoSmithKline's Lamictal, generics) and divalproex (Abbott/Sanofi-Aventis's (…)

[Read article]

[Source: Medical News Today]

26.08.2010 | Business Wire: Research and Markets: Sales of Pharmaceuticals in Sri Lanka Are Expected To Increase From LKR38.97bn (U$339mn) In 2009 to LKR43.88bn (US$388mn) In 2010 | Business Wire

DUBLIN-(BUSINESS WIRE)-Research and Markets(http:/www.researchandmarkets.com/research/880d0b/sri_lanka_pharmace) has announced the addition of the "Sri Lanka Pharmaceuticals and Healthcare Report Q3 2010" report to their offering. Sri Lanka Pharmaceuticals and Healthcare (…)

[Read article]

[Source: Business Wire]

26.08.2010 | Business Wire: Research and Markets: This Essential World Pharmaceutical Market Analysis Digest Guide with Forecasts Predicts the Market Will Stabilize the Years Up To 2014 | Business Wire

DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/e03d6e/world_pharmaceutic) has announced the addition of the "World Pharmaceutical Market Analysis - A Digest Guide, 2010-2014" report to their offering. World Pharmaceutical Market (…)

[Read article]

[Source: Business Wire]